- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06295744
Outcomes and Cosmesis With Whole Breast Irradiation and Boost
Patient-Reported Outcomes and Cosmesis Following Five Fraction Whole Breast Irradiation With Simultaneous Integrated Boost
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study population will consist of 50 participants with non-metastatic, early-stage invasive breast cancer or ductal carcinoma in situ (DCIS). Eligible patients will include those with a biopsy proven invasive breast cancer or DCIS, greater than or equal to 18 years of age, undergoing breast conserving surgery and adjuvant radiation therapy at UW Health with an indication for WBI with tumor bed boost. Selection need for boost and radiation treatment field design and pre-tx imaging are at the discretion of the treating provider.
Accrual will occur over 5 years at UW Health. Participants will complete 5 treatment visits and 7 study visits over the course of approximately 5.5 years. Research-related outcome measures - MD assessments (e.g., cosmesis) PROMs, and AEs -- will be assessed prior to treatment start, at the 6-week follow-up visit, as well as at 12-, 24-, 36-, 48- and 60-month follow-up visits. Study participation ends after completion of the 60-month follow-up visit.
Objective
• To assess two-year cosmetic outcomes in patients treated with ultra-short WBI with a SIB.
Secondary Objectives
- To assess PROMs via BREAST-Q in patients treated with ultra-short WBI with SIB.
- To assess acute toxicities in patients treated with ultra-short WBI with SIB.
- To assess late toxicities in patients treated with ultra-short WBI with SIB.
- To assess ipsilateral breast tumor recurrence in patients treated with ultra-short WBI with SIB.
- To assess overall survival (OS) in patients treated with ultra-short WBI with SIB.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Cancer Connect
- Phone Number: 800-622-8922
- Email: clinicaltrials@cancer.wisc.edu
Study Locations
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- Recruiting
- UW Carbone Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Ability to understand and the willingness to sign a written informed consent document
- Histologically confirmed early stage (stage T1-T2) invasive carcinoma of the breast or DCIS
- Breast conserving surgery with negative margins and negative nodes (surgical axillary staging not mandatory), stage N0 or Nx
- Treatment plan should include breast conserving surgery and adjuvant whole breast irradiation (WBI) therapy delivered with 3D-CRT or IMRT techniques
- Treatment plan includes breast tumor bed boost
- Willingness to comply with all study procedures and be available for the duration of the study
Exclusion Criteria:
- Mastectomy of ipsilateral breast
- Lack of histologic diagnosis
- Histologic involvement of the axillary or regional nodes or metastatic disease
- Accelerated partial breast irradiation treatment plan
- Previous history of non-breast malignancy diagnosed in the past 5 years except for basal or squamous cell cancer of the skin
- Previous history of chest radiation therapy
- Previous history of ipsilateral breast cancer
- Concurrent cytotoxic chemotherapy
- Active connective tissue disease including scleroderma
- Inability or unwillingness to return for required follow up visit
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: WBI with SIB
|
WBI with SIB delivered over 5 fractions
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Harvard Breast Cosmesis Scale Score
Time Frame: up to 2 years post-treatment (treatment ends up to 5 weeks on study)
|
4-point scale where 1 is excellent, 2 is good, 3 is fair, and 4 is poor.
|
up to 2 years post-treatment (treatment ends up to 5 weeks on study)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in BREAST-Q Score
Time Frame: baseline, 6 weeks post-RT, 12 months post-RT, 24 months post-RT, 60 months post-RT (treatment ends up to 5 weeks on study)
|
The BREAST-Q questionnaire is scored from 0-100 where higher scores indicate better outcomes in each of 5 domains: Psychosocial Well-Being, Sexual Well-Being, Cancer Worry, Fatigue, and Impact on Work.
|
baseline, 6 weeks post-RT, 12 months post-RT, 24 months post-RT, 60 months post-RT (treatment ends up to 5 weeks on study)
|
Incidence of Acute Toxicities
Time Frame: up to 90 days post-RT (treatment ends up to 5 weeks on study)
|
Acute toxicities (including breast dermatitis, induration) will be assessed after final treatment within 90 days of radiation therapy completion using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.
|
up to 90 days post-RT (treatment ends up to 5 weeks on study)
|
Incidence of Late Toxicities
Time Frame: up to 60 months on study
|
Late toxicities (including induration, fibrosis, shrinkage, and telangiectasia) will be assessed greater than 90 days of radiation therapy completion using CTCAE version 5.0
|
up to 60 months on study
|
Ipsilateral Breast Tumor Recurrence-Free Survival
Time Frame: up to 60 months on study
|
Kaplan-Meier curves will be used to estimate ipsilateral breast tumor recurrence-free survival.
|
up to 60 months on study
|
Overall Survival (OS)
Time Frame: up to 60 months on study
|
Kaplan-Meier curves will be used to estimate OS.
|
up to 60 months on study
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jessica Schuster, MD, UW Carbone Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 2023-1724
- A533300 (Other Identifier: UW Madison)
- Protocol Version 2/5/2024 (Other Identifier: UW Madison)
- UW23114 (Registry Identifier: UWCCC OnCore ID)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Early-stage Breast Cancer
-
Dana-Farber Cancer InstituteCompletedEarly Stage Breast Cancer | Breast Cancer Stage I | Breast Cancer Stage IIUnited States
-
Jonsson Comprehensive Cancer CenterDaiichi Sankyo Co., Ltd.; Translational Research in Oncology-U.SRecruitingInvasive Breast Cancer | Stage II Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Hormone Receptor Positive Breast Carcinoma | Early-stage Breast Cancer | Stage III Breast CancerUnited States
-
Tanvex BioPharma USA, Inc.CompletedBreast Cancer | Breast Neoplasms | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Early-stage Breast CancerBelarus, Chile, Georgia, Hungary, India, Mexico, Peru, Philippines, Russian Federation, Ukraine
-
Stanford UniversityTerminatedBreast Cancer | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer Metastatic Breast CancerUnited States
-
Stanford UniversityNational Institutes of Health (NIH); University of California; Breast Cancer... and other collaboratorsActive, not recruitingBreast Cancer | Breast Cancer Non-invasive Breast Cancer | Breast Cancer Early Stage Breast Cancer (Stage 1-3)United States
-
Shandong Cancer Hospital and InstituteRecruitingEarly-stage Breast Cancer | Breast Conserving SurgeryChina
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Active, not recruitingStage 0 Breast Cancer | Cancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Early-Stage Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
MedStar Franklin Square Medical CenterMedstar Health Research InstituteActive, not recruitingEarly Stage Breast CancerUnited States
-
Fudan UniversityHuazhong University of Science and Technology; LinkDoc Technology (Beijing)...RecruitingEarly-stage Breast CancerChina
-
British Columbia Cancer AgencyActive, not recruitingEarly Stage Breast CancerCanada
Clinical Trials on Radiation Therapy
-
NRG OncologyNational Cancer Institute (NCI)RecruitingUnrectable or Locally Recurrent Hepatocellular CarcinomaUnited States
-
Medical College of WisconsinRecruitingHead and Neck CancerUnited States
-
Medical College of WisconsinRecruitingResectable Head and Neck Squamous Cell CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Completed
-
University of California, San FranciscoVarian Medical SystemsRecruitingStage IV Anal Cancer AJCC v8 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Postneoadjuvant Therapy Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedAnn Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | Extranodal Marginal Zone LymphomaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedBrain Tumor | Central Nervous System TumorUnited States, Canada, Australia, Puerto Rico, Switzerland, New Zealand
-
Medical College of WisconsinActive, not recruitingHigh-Dose Lymph Node Intensity Modulated Radiation Therapy and Hypofractionated Prostate (SIB) (SIB)Prostate CancerUnited States
-
Changhai HospitalRecruitingLocalized Prostate CancerChina
-
NYU Langone HealthCompletedBreast CancerUnited States